Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Up 12.6% in December

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 167,300 shares, a growth of 12.6% from the December 15th total of 148,600 shares. Based on an average trading volume of 64,600 shares, the short-interest ratio is currently 2.6 days. Currently, 2.0% of the shares of the company are sold short.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC boosted its holdings in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the quarter. HB Wealth Management LLC owned about 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. 2.14% of the stock is currently owned by institutional investors.

Alterity Therapeutics Stock Performance

Shares of NASDAQ:ATHE opened at $3.42 on Monday. The firm has a 50 day simple moving average of $2.30 and a 200 day simple moving average of $1.72. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $4.71.

Analysts Set New Price Targets

Separately, Maxim Group initiated coverage on shares of Alterity Therapeutics in a research report on Thursday, December 12th. They issued a “buy” rating and a $8.00 target price for the company.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.